Glycoengineering Chinese hamster ovary cells: a short history | Zendy

Roberto Donini | Zendy; Stuart M. Haslam | Zendy; Cleo Kontoravdi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glycoengineering Chinese hamster ovary cells: a short history

Author(s) -

Roberto Donini,

Stuart M. Haslam,

Cleo Kontoravdi

Publication year - 2021

Publication title -

biochemical society transactions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.562

H-Index - 144

eISSN - 1470-8752

pISSN - 0300-5127

DOI - 10.1042/bst20200840

Subject(s) - chinese hamster ovary cell , glycoprotein , immunogenicity , glycosylation , ovary , recombinant dna , antibody , microbiology and biotechnology , chemistry , computational biology , biology , biochemistry , immunology , receptor , endocrinology , gene

Biotherapeutic glycoproteins have revolutionised the field of pharmaceuticals, with new discoveries and continuous improvements underpinning the rapid growth of this industry. N-glycosylation is a critical quality attribute of biotherapeutic glycoproteins that influences the efficacy, half-life and immunogenicity of these drugs. This review will focus on the advances and future directions of remodelling N-glycosylation in Chinese hamster ovary (CHO) cells, which are the workhorse of recombinant biotherapeutic production, with particular emphasis on antibody products, using strategies such as cell line and protein backbone engineering.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research